A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder
Journal of Psychopharmacology March 13, 2026 Francisco Moreno, Katja Ehrmann Allen, Christopher B. Wiegand et al. 3 citations
BACKGROUND: Current treatments for obsessive-compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed. AIMS: This randomized clinical trial evaluated safety, tolerability, and benefit of multiple psilocybin doses...